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PENEROKAAN ‘REAL TIME PCR’ SEBAGAI KAEDAH PENDIAGNOSAN 
BARU BAGI SINDROM ‘FRAGILE X’. 
 
ABSTRAK 
 
Sindrom “Fragile X” (FXS) adalah di antara penyakit kerencatan mental dikalangan 
lelaki yang paling kerap di warisi. Penyakit ini disebabkan oleh gen FMR1 yang tidak 
normal melalui pemanjangan jujukan CGG dan hipermetilasi pada bahagian 
promoternya. Alel termetilasi biasanya boleh menyebabkan kerencatan transkripsi dan 
menjurus kepada kehilangan penghasilan Protein ”Fragile X Mental Retardation” 
(FMRP). Modifikasi kimia dari sitosin kepada urasil dengan rawatan natrium bisulfit 
memberikan kaedah tambahan bagi kajian metilasi DNA yang boleh mengelakkan 
penggunaan analisis pemblotan Southern. DNA genomik diekstrak daripada darah 
periferal pesakit yang telah dikenalpasti secara klinikal sebagai pesakit FXS. Sampel-
sampel tersebut dirawat dengan natrium bisulfit diikuti dengan amplifikasi 
menggunakan ”Real Time Multiplex Methylation Specific PCR” (RT-M-MSPCR) 
dengan gen XIST sebagai kawalan dalaman, diikuti dengan analisis graf lebur. 
Keputusan yang didapati menunjukkan semua sampel kawalan yang mana status 
metilasinya telah diketahui telah dapat dikesan dengan tepat menggunakan kaedah RT-
M-MSPCR. Bagi tujuan pengesahan kaedah yang telah dilakukan, status metilasi bagi 
45 orang pesakit lelaki telah dapat kesan dengan tepat berdasarkan perbandingan dengan 
keputusan pemblotan Southern. Tiga puluh sembilan sampel telah dikenal pasti sebagai 
tidak termetilasi, 4 sampel termetilasi penuh dan 2 sampel mengandungi kedua-dua alel 
termetilasi dan tidak termetilasi dan dikategorikan sebagai mozaik. Kaedah pengesanan 
 xxi
disahkan sebagai spasifik kerana suhu lebur bagi kedua-dua alel termetilasi dan tidak 
termetilasi masing-masing di dalam julat variasi yang kecil iaitu 84.91 ± 0.41ºC bagi alel 
tidak termetilasi, dan 90.57 ± 0.34 ºC bagi alel termetilasi. Peratusan metilasi bagi 
sampel mozaik juga boleh diperolehi dengan peratusan metilasi serendah 5%. 
Walaubagaimanapun, peng-di-aktifan rawak pada metilasi pesakit perempuan 
menyebabkan status pramutasi dan mutasi penuh pada perempuan tidak dapat dibezakan. 
Oleh kerana pesakit FXS lelaki adalah lebih kerap berbanding perempuan, maka 
kelemahan ini bukanlah penyumbang kepada masalah besar dalam saringan pesakit 
FXS. Kesimpulannya, hasil kajian ini menunjukkan RT-M-MSPCR adalah jitu, murah 
dan 100% sama sepesifik juga sensitif jika dibandingkan dengan kaedah pemblotan 
Southern. Kaedah pengesanan yang baru ini juga sangat mudah dilakukan bagi saringan 
FXS dalam jumlah yang banyak kerana ia cepat dan mudah dilaksanakan terutamanya 
bagi sampel yang mempunyai kuantiti yang sangat sedikit.  
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EXPLORATION OF REAL TIME PCR AS A NEW DIAGNOSTIC METHOD OF 
FRAGILE X SYNDROME 
 
ABSTRACT 
 
Fragile X Syndrome (FXS) is the most common form of inherited mental retardation in 
males caused by FMR1 gene abnormality associated with CGG repeats expansion and 
hypermethylation status of its promoter. Methylated alleles usually lead to 
transcriptional inhibition and consequently loss of Fragile X Mental Retardation Protein 
(FMRP) production. Chemical modification of cytosine to uracil by sodium bisulfite 
treatment has provided an additional method for the laboratory diagnosis of FXS, thus 
avoiding the use of the laborious Southern blot analysis, which is the gold standard test 
for FXS diagnosis. Thus, a study was done to explore a rapid, easy, reliable and cheap 
method for FXS diagnosis that can replace the laborious, time consuming and expensive 
Southern blot method. Genomic DNA was extracted from peripheral blood of 45 
clinically diagnosed FXS patients. Samples were treated with sodium bisulfite followed 
by amplification using real-time multiplex methylation specific PCR (RT-M-MSPCR) 
with XIST gene as an internal control, followed by melting curve analysis. Our results 
showed all control samples with known methylation status were correctly diagnosed 
using Real Time Multiplex Methylation Specific PCR. For method validation purpose, 
the methylation status of other 45 male patients sample were also successfully diagnosed 
using our RT-M-MSPCR method and were concordance with the results of the Southern 
blot. Thirty nine samples were found to have unmethylated allele, 4 samples were fully 
methylated and 2 samples have both methylated and unmethylated alleles implying a 
 xxiii
diagnosis of mosaicism. The method that was developed was confirmed to be specific as 
the melting temperature of both methylated and unmethylated FMR1 promoter was 
found to be varied in only a small range of melting temperature differences of 84.91 ± 
0.41ºC and 90.57 ± 0.34 ºC for methylated and unmethylated promoter respectively. The 
methylation percentage of mosaic patients were successfully calculated with a detection 
ability as low as 5% methylation percentage. However, due to random inactivation, 
female methylation status cannot be identified thus premutation and full mutation 
females cannot be differentiated from normal females. Having said that, male patients 
are more commonly diagnosed with FXS, thus this is not a major limitation for FXS 
screening. In conclusion, our results showed that RT-M-MSPCR is reliable, inexpensive 
and have 100% equal sensitivity as well as specificity compared with Southern blot. 
This newly developed method is also very convenient in screening large number of male 
FXS patients as it is non-time consuming and easy to perform especially when there is a 
low quantity of samples (final concentration of genomic DNA) that need to be 
sensitively and accurately determined. 
  
CHAPTER 1 
 
LITERATURE REVIEW 
 
1.1 Research Background. 
1.1.1 Mental Retardation 
 
Mental retardation is a term used when a person has a significant below average 
intellectual functioning accompanied with limitations in adaptive functioning in at least 
two of the skill areas such as communication, self care, home living, social/ 
interpersonal skills, use of community resources, self-direction, functional academic 
skills, work, leisure, health, and safety (American Psychiatric Association, 1994). 
 
Some mental disorders have a definite etiological basis. It maybe due to environmental 
effects such as toxin, infections, trauma, perinatal anoxia, biochemical, chromosomal 
abnormalities or Mendelian genetic disorder. In 2005, J. Hamel reported that mental 
retardation is one of the main reasons for referral in pediatric, child-neurology and 
clinical genetic clinic.  
 
The prevalence of mental retardation in developed countries is thought to be 2–3% 
(Leonard and Wen, 2002). Compared to female, more males were found to be mentally 
  2 
retarded in a population (Herbst et al., 1980), probably as a result of X-linked mental 
retardation condition (XLMR).  
 
In 2001, Chelly and Mandel reported that at least 23 of XLMR genes have been 
identified. Mutation in these 23 genes may lead to syndromic (S-XLMR) and non-
syndromic (NS-XLMR), depending on whether other abnormalities in addition to mental 
retardation are found on physical examination, laboratory investigation and brain 
imaging. The most frequent example of syndromic XLMR is Fragile X Syndrome 
(Hamel, 2005). 
  
1.1.2 Fragile X Syndrome 
 
Fragile X Syndrome (FXS) is the most frequent type of inherited mental retardation. The 
prevalence of Fragile X Syndrome is approximately 1 in 4000 males and 1 in 8000 
females (Crawford et al., 2001). As reported, approximately 1 in 700 females are 
carriers and the frequency of premutation in general population is approximately 1 in 
259 females and 1 in 813 males (Turner et al., 1996; Rousseau et al., 1995).  
 
Fragile X Syndrome is caused by an unstable (CGG)n
 
 tri-nucleotide repeat located in the 
Fragile-X Mental Retardation 1 gene (FMR1) [MIM 309550] at the chromosomal locus 
Xq27.3 (Oberle´ et al., 1991; Verkerk et al., 1991; Yu et al., 1991). 
In 1943, J. Purdon Martin and Julia Bell described the first family with Fragile X 
Syndrome. In this family, 11 male members were severely mentally retarded, and the 
  3 
inheritance pattern appeared to be X-linked. X-linked traits are inherited on the X 
chromosome and are more common in males, who have only one X chromosome, than 
in females, who have two. 
 
A constriction near the end of the long arm (q arm) of the X chromosome in four 
mentally retarded males and two of their mentally normal female relatives were reported 
by Herbert Lubs in 1969. This constriction made the X chromosome appear to be 
wrecked. Hence the syndrome was named "Fragile X Syndrome". 
 
More families were identified as having mental retardation with the same chromosome 
fragile site in the late 1970s. Moreover, in 1977 Sutherland discovered that the ability to 
distinguish this fragile site relied on the chemicals used to study patients' chromosomes 
and this important observation helped develop the first diagnostic test for Fragile X 
Syndrome.  
 
1.1.3 Hereditary pattern 
 
Fragile X Syndrome has a complex inheritance pattern. Carrier females can pass their 
CGG repeats mutation to their children of either sex. However, carrier males, also 
referred to as normal transmitters (NT), can only transmit the CGG repeats mutation to 
their daughters. This is because in all X-linked disorders there is no male-to-male 
inheritance. Usually, carrier males show no physical or mental features of the syndrome 
and express no or little fragile site expression during the cytogenetic analysis.  
 
  4 
It was estimated that 20% of males carrying the mutation have no phenotypic 
expression; they are called normal transmitting males. Among carrier females, 55% were 
found to express Xq27.3 fragile site, and one third of the carriers are mentally impaired. 
However, daughters of normal transmitting males appeared to have little or no 
phenotypic expression (Heitz and Mandel, 1992). 
 
Fragile X premutation gene does not expand in its CGG repeat size when passed from an 
unaffected father to his daughters. However, in female, they are at risk for having 
children with a stretched full mutation. Thus, whenever one person in a family is found 
to have Fragile X Syndrome, the mutation of the FMR1 gene can almost constantly be 
traced back to previous generations, although many of the gene carriers in the family 
may be unaffected. 
 
Although the location of this fragile site at X chromosome established that Fragile X 
Syndrome was indeed X-linked, inheritance of this disorder was obviously not 
distinctive for an X-linked disorder. In 1985, Sherman et al. verified that the risk of 
expressing mental retardation was dependent on the individual's position in a pedigree, 
with risk increasing in later generations. This observation is recognized as the "Sherman 
paradox" and crucial in understanding the genetic mutation that causes Fragile X 
Syndrome. 
 
In Sherman paradox, it was hypothesized that the mutation arises in a two step process. 
The first mutation leads to a "premutation" state with no clinical symptoms and the 
second mutation alters the premutation state to a "full mutation". (Sherman et al., 1985) 
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Sherman paradox also described the phenomenon where the low penetrance occurs at 
approximately 18% in brothers of normal transmitting males and more than 80% 
penetrance in brothers of affected males.  
 
1.1.4 Phenotypic Characteristics 
 
People affected by Fragile X syndrome normally have a normal life span. It is because 
they do not suffer from any major medical problems and thus are generally healthy. 
However, there are some medical features which may be more common in Fragile X 
syndrome patients. Clinically, patients with Fragile X syndrome show wide variability of 
phenotype. The major clinical appearance in adult males is moderate mental retardation, 
with an IQ in the range of 40-70. However, mild mental retardation also been reported 
(Simola, 1984; Sutherland & Hecht, 1985; Fisch et al., 1991). 
 
1.1.4.1 Intelligence Quotient (IQ) 
 
Intelligence quotient (IQ) is widely used to define human general intellectual 
functioning (table 1.1). IQ less then 70 is classified as mental retardation. A person with 
mild mental retardation will have an IQ of 70-50 followed by moderate mental 
retardation with IQ range of 35-49. IQ range of 20-34 belongs to the severe mental 
retardation group and IQ less then 20, profound mental retardation. Approximately 2–
3% of the population are mild to moderate intellectual disability and 0.5–1% of the 
population have from the moderate to severe mental retardation group (Raymond, 2005). 
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Table 1.1: Intelligence Quotient (IQ) Scores Reported by Different Authors in the 
normal population. 
 
Level 
Intelligence Quotient (IQ) 
Sparrow et 
al., 1987*  
Heber 
(AAMR, 
1959, 
1961)* 
Grossman 
(AAMR, 
1973)* 
Grossman 
(AAMR, 
1983)* 
Ropers & 
Hamel, 
2005) 
Borderline 70 – 79 85 – 84  - - 70-85 
Mild MR 50 – 68 52 – 67  52 – 67  50 – 55~70 50-70 
Moderate 
MR 
40 – 49 36 – 51 36 – 51 35 – 40 to  
50 - 55 
35-50 
Severe MR 30 – 39 20 – 35 20 – 35 20 – 25 to 
35 – 40 
20-35 
Profound 
MR 
< 20 < 20 20 < 20 or < 25 <20 
*Source: Hussein, 1998. 
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1.1.4.2 Physical Characteristic 
 
The physical characteristic in Fragile X patients include several dysmorphic features 
such as long and narrow face, prominent jaw, large ears, prominent forehead and 
macroorchidism. Affected females usually exhibit a similar but less severe phenotype 
than affected males.  
 
Besides that, connective tissue abnormalities such as joint hypermobility also often arise. 
Joint hypermobility, also known as hyperlaxity or hyperextensibility is the term used for 
joints that stretch further than normal. For example, some hypermobile people can bend 
their thumbs backwards to their wrists, bend their knee joints backwards, or lay their leg 
behind the head. 
 
Abnormalities of electroencephalography (EEG) are frequently found in Fragile X 
patients. However, epileptic seizures are rare (Opitz & Sutherland, 1984; Simola, 1984). 
In Fragile X patients, the EEG pattern is usually similar to rolandic epilepsy pattern. In 
this pattern of EEG, sharp waves with in the centrotemporal regions of the brain are 
discharge during sleep. Other EEG patterns that have been previously reported include 
theta rhythm, diffuse or multifocal spike waves, and a diffuse slowing background 
activity. Females with Fragile X Syndrome tend to present with unspecific EEG 
patterns. Thus, the frequency of epilepsy is lower (Feliciano, 2005).  
 
In Fragile X Syndrome, it is hypothesized that the presence of EEG abnormalities such 
as excessive neuronal excitation and spiking could be caused by the dendritic spine 
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anomalies that can be observed in the brain of Fragile X Syndrome patients. Another 
theory proposed on GABAnergic system dysfunction due to the absence of FMRP 
(Feliciano, 2005). 
 
Signs like hyperactivity, attention deficiency, learning disabilities and delay in learning 
language are often the first sign that lead to suspicion of Fragile X syndrome (Fryns et 
al., 1984, Sudhalter et al., 1991). Other behavioral abnormalities are also frequently 
observed in Fragile X males that include autistic-like behavior such as hand flapping, 
hand biting, rocking, poor eye contact and repetitive speech patterns, perseveration and 
echolalia. However, behavioral abnormalities occasionally happen in females (Reiss & 
Freund, 1992).  
 
Usually, the clinical presentation of Fragile X Syndrome is variable and not all physical 
or behavioral symptoms are shown in every patient and the somatic signs are mostly 
apparent after puberty. Additionally, some patients do exhibit other unusual phenotypic 
profiles resembling Prader-Willi Syndrome (de Vries & Niermeijer, 1994) and Sotos 
Syndrome (Beemer et al., 1986). Therefore, Fragile X Syndrome is often difficult to 
diagnose on a clinical basis alone especially prior to puberty. 
 
1.1.5 Neurological abnormality 
 
Recently, a progressive neurological abnormality has been identified, affecting male 
carriers beyond the age of 50 years old. The male carriers are generally healthy and have 
normal to above average intelligence until they reach their middle age. After the age of 
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50 years old, the men will have Fragile X-associated Tremor/Ataxia Syndrome 
(FXTAS) and is characterized by tremors, balance problems and dementia that usually 
progress with age. 
 
Due to the symptoms, persons with FXTAS were wrongly diagnosed as having 
Parkinson’s disease, multiple systems atrophy-cerebellar type, sporadic 
olivopontocerebellar degeneration, or essential tremor. The correct diagnosis is however 
very crucial for appropriate treatment (Hagerman et al., 2001).  
 
1.1.6 Structure and Function of FMR1 gene 
 
A gene named FMR1 that caused Fragile X Syndrome was first cloned in 1991. The size 
of FMR1 gene is about 40 kilobases (kb), encoding 3.9 kb of mRNA, consisting of   
approximately 0.2 kb of a 5’ untranslated region, a 1.9 kb protein coding region, and a 
1.8 kb 3’ untranslated region. (Verkerk et al., 1991) The FMR1 gene is composed of 17 
exons and the first exon is 9.9kb.  
 
In most cases, Fragile X Syndrome occur due to elongation of a polymorphic repeat of 
(CGG)n
 
 stretch located at 5’- untranslated region of the FMR-1 gene (Oberlé et al., 
1991; Fu et al., 1991; Kremer et al., 1991). FMR1 transcription is suppressed when the 
CpG island in its promoter region located 250 bp upstream from the CGG repeats is 
stretched and methylated (Eichler et al., 1993). 
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Repeat sequence of (CGG)n
 
 in normal individual is from 5 to 53 repeats per individual. 
In Fragile X premutation, the CGG triplet repeat number is from 60 to 200 repeats and 
become progressively unstable as the number of repeats increase. The bigger the extent 
of a woman’s premutation CGG repeats, the higher the risk of expansion to a full 
mutation in her children (Sherman et al., 2005). 
Even though the repeat range of normal and premutation individual has been identified, 
there is still no clear boundary between the upper limit of normal and the lower limit of 
the premutation range. Thus, alleles with 45-55 CGG repeats fall within the gray zone 
category. Some alleles in this category are unstable and can enlarge from generation to 
generation while others are stably inherited (Fu et al., 1991).  
 
When the CGG repeats is 200 or more, the stretched repeat sequence and flanking CpG 
island are usually hypermethylated. This phenomenon will cause transcriptional 
silencing of the gene that is commonly referred to as the FMR1 full mutation (Reiss et 
al., 1995).  
 
Normally, AGG interruptions of CGG triple repeat sequences take place once every nine 
or ten CGG repeats. The majority (64%) of normal alleles consisting of 5–50 CGG 
repeats have two or more AGG interruptions. However, most of the premutation alleles 
(50–200 repeats) have a single or no interruption (Eichler et al. 1995). In 1997, Chen et 
al. had revealed that the sequence organization of the normal Caucasian individual’s 
alleles is 10A9A9 and Asians normally had the 9A9A9. 
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For Asians, the most frequent allele size in normal individuals was 29 (50%) followed 
by 30 repeats (22%) but for the Caucasians, the most common size of (CGG)n
 
 was 30 
repeats followed by 29 repeats. For Native Americans from Pacific Northwest, the most 
frequent allele size was also 29 and 30 repeats with the remaining alleles of not more 
than 39 repeats (Chen et al., 1997). 
1.1.7 Fragile X Mental Retardation Protein 
 
Generally, FMR1 gene code for a protein called Fragile X Mental Retardation Protein 
(FMRP). This protein is a selective RNA binding protein which controls other mRNA, 
mainly in the central nervous system which probably plays an important function in 
brain development (Abitbol et al., 1993). FMRP is normally expressed in neurons, 
lymphocytes, fibroblasts, testes and placenta (Siomi et al., 1993). In a normal brain, 
FMRP is expressed in large amount in the cortex, hippocampus and cerebellar granule 
cell layer. 
 
The 4.4 kb full length mRNA from the FMR1 gene can code for a protein with a 
maximum length of 632 amino acids and 70–80 kDa of molecular mass (Verheij et al., 
1993). However, from 20 different transcripts that might be produced by alternative 
splicing, only 4–5 of them and their corresponding protein products are actually detected 
in various tissues (Ashley et al., 1993). 
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Source:  Bardoni & Mandel, 2002. 
Figure 1.1: The functional structure of FMRP.   
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To perform its role, FMRP binds to its own mRNA to a sequence containing a G quartet 
structure that is also found in some of the other mRNAs. As in figure 1.1, FMRP 
contains two types of RNA-binding motifs, 2 KH domains and an RGG box (Ashley et 
al., 1993). The importance of these domains was shown by discovery of a mentally 
retarded male with a point mutation that results in a second KH domain amino acid 
substitution (I304N) (De Boulle et al., 1993). In 2001, Schaeffer et al. reported that 
FMRP binds to its own mRNA via a purine quartet that is found at the C-terminal end of 
the part coding for the open reading frame. 
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At the subcellular level, FMRP is found in the cytoplasm and it is mainly associated 
with actively translating ribosomes (Khandjian et al., 1996). FMRP can dimerize either 
with itself or with the related proteins like FXR1P or FXR2P (Tamanini et al., 1999). 
These proteins have both a nuclear export signal at the C terminus and location signal 
within its N terminus. (Eberhart et al., 1996) The presence of these two patterns suggests 
that FMRP can move between the cytoplasm and the nucleus and might have a function 
in the transport of certain specific RNAs from the nucleus to the cytoplasm. 
 
In 2001, Brown et al. identified that some of the FMRP-associated mRNAs were 
underrepresented in polysomes in patient cells but the mRNAs are equivalent in the cell 
itself. This alteration in polysome distribution of G quartet-containing mRNAs can be 
explained by assuming that FMRP is required to bring those mRNAs to the translating 
ribosomes. The misregulation of certain mRNAs might be one of the causes of mental 
retardation seen in Fragile X Syndrome. 
 
1.1.8 Mutation that cause Fragile X Syndrome 
 
Expansion of (CGG)n repeats was identified to be associated with hypermethylation of 
the region and  may lead to the loss of activity of  FMR1 gene in almost all fragile X 
cases. However, other alterations in the FMR1 gene can also be one of the origins of 
Fragile X Syndrome For example, intragenic point mutations (Lugenbeel et al., 1995) 
and deletions. In 1997, Wolff et al. observed that large deletion may eliminate the entire 
FMR1 gene and also the flanking sequence of the gene that may lead to Fragile X 
Syndrome. However, in 1992, Wöhrle et al. claimed that smaller deletions may also lead 
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to Fragile X Syndrome by removing the proximal part of the FMR1 gene from the 5' 
upstream region to exon one until exon eleven. 
 
In 1993, De Boulle et al. characterized a point mutation of a single base pair 
transversion from T to A that changed an Ile codon 304 to an Asn codon (Ile304Asn). 
Although the altered protein differs by only one amino acid, location of this substitution 
in one of the KH domains appears to totally ruin the normal function of FMRP. So, in 
spite of normal mRNA levels, this mutation may lead to a particularly severe phenotype. 
 
In 1995, Lugenbeel et al. reported other intragenic mutations in the FMR1 gene of a 
typical clinical phenotype fragile X patient. The mutation was a one base pair deletion in 
exon 5 resulting in a frameshift that may lead to a premature translational termination of 
the protein product. A two-basepair change in the splice acceptor site of exon 2 was also 
predicted, resulting in two transcripts of reduced size detected by RT-PCR.  
 
1.1.9 FMR1 gene Hypermethylation Mechanism 
 
Methylation of DNA mostly occurs at the carbon-5 position of cytosine residues within 
CpG island (Gardiner et al., 1987). CpG islands are the GC rich region of DNA. On 
average, the CpG islands are 0.5-4.0 kb in length and are unmethylated in normal tissues 
when initiated in the 5’ region of genes (Bird, 2002). This CpG islands are frequently 
located within the promoter region of human genes. Methylation within the CpG islands 
was shown to be associated with transcriptional inactivation and functional silencing of 
the corresponding gene due to chromatin compression (Jones & Takai, 2001). 
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DNA methylation is a major epigenetic modification of human genomic DNA. It is 
catalyzed by DNA methyltransferase enzymes that perform the addition of a methyl 
group to the carbon 5 of the cytosine ring in CpG nucleotides. This condition takes place 
only at cytosine bases that are located at 5’ to a guanosine in each CGG trinucleotide 
repeats within a mammalian genome (Bird, 2002 & Gutierrez et al., 2003).  
 
In the methylation mechanism, excessive expansion of the CGG repeat allows the 
formation of abnormal (non Watson-Crick) structures that most probably formed on the 
lagging strand during replication (Darlow and Leach, 1998). These abnormal structures 
may attract DNA methyltransferases (Kho et al., 1998). The hypermethylation of the 
CGG repeat would perhaps spread to the surrounding CpG island through indirect 
(MeCP2/MBD mediated) interference on transcription that may cause the ‘de novo’ 
methylation of the promoter followed by gene silencing.  
 
1.1.10 Fragile X Mental Retardation 2 Gene (FMR2 gene) 
 
FMR2 is a gene adjacent to the FMR1 gene. It consist of FRAXE which is a folate-
sensitive fragile site situated in Xq28 that lay approximately 600kb distal to the FRAXA 
(Sutherland et al., 1992; Knight et al.,1993). Molecularly, individuals that express 
FRAXE had extension of a CCG repeat adjacent to a CpG island. Normal individuals 
show 4–39 copies of the polymorphic FRAXE CCG repeat, while individuals that 
express the fragile site usually have more than 200 copies and their CpG island was fully 
methylated (Knight et al., 1993). Mutation of FRAXE may lead to a less specific and 
milder form of mental retardation.  
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Apart from the FRAXA and FRAXE, FRAXF (Parrish et al., 1994), FRA16A 
(Nancarrow et al.,1994) and FRA11B (Jones et al.,1995) were also identified to be able 
to undergo expansion and hypermethylation and are also associated with fragile sites. 
However, all these repeats are located in the untranscribed regions of the genome and 
have not been associated with any genetic disorder when 'fully' expanded and 
hypermethylated. 
 
1.2 Gold Standard of Fragile X Syndrome Laboratory Diagnosis  
1.2.1 Cytogenetic analysis 
 
According to the Oxford Concise Medical Dictionary, cytogenetics is defined as a 
branch of biology that deals with the study of heredity and variation by the methods of 
both cytology and genetics. It concerned with the study of chromosomes and cell 
division that includes routine analysis of chromosomes such as G-banding, C-banding, 
Unbanded-Giemsa and other cytogenetic banding techniques, as well as molecular 
cytogenetics such as fluorescent in situ hybridization (FISH) and comparative genomic 
hybridization (CGH). Chromosomes were first observed in plant cells by Karl Wilhelm 
von Nägeli in 1842. Their behavior in animal (salamander) cells was illustrated by 
Walther Flemming, in 1882.  
 
In cytogenetics technique, chromosomal analysis starts with white blood cells culture in 
a medium followed by treating cells in a hypotonic solution, which will swell the cells 
and spread the chromosomes. Mitosis is later arrested in metaphase by a solution of 
colchicines that is applied before squashing the preparation on the slide forcing the 
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chromosomes into a single plane. The analyses of the result are done by capturing the 
chromosomal image followed by karyotyping.  
 
Fragile site at Xq27.3 (FRAXA) is one of the rare folate-sensitive fragile sites found in 
human chromosomes that can be identifed by cytogenetics technique (Sutherland, 1977). 
Since the detection of a unique type of X-linked mental retardation occurring in 
combination with a fragile site on the end of the long (q) arm of the X chromosome, 
efforts were made to demonstrate this oddity in lymphocytes (Lubs, 1969; Sutherland, 
1977), lymphoblastoid cell lines and fibroblasts (Jacky and Dill, 1980; Tommerup et al., 
1981). This cytogenetics test was done on affected males and female carriers as well as 
in amniotic fluid cells of carriers in order to perform prenatal diagnosis (Jenkins et al., 
1981). 
 
The expression of the fragile site on the X chromosome is well-known to be dependent 
on culture conditions, such as the content of folic acid and thymidine in the medium 
(Sutherland, 1977). Therefore, either a folic acid deficient medium such as TC 199 
(Sutherland, 1977) or dihydrofolate reductase inhibitors like methotraxate (MTX) or 
thymidylate synthetase such as 5-fluorodeoxyuridine (FUDR) are used to demonstrate 
the presence of a folate sensitive fragile site at the X chromosome (Glover, 1981). 
 
Although cytogenetic methods have improved tremendously, expression of fragile site at 
Xq 27.3 can never be detected in all metaphase spread of the patient’s cell. The 
expression usually varies from 2% to 60% of the metaphase examined. The frequency of 
X chromosomes with fragile site appears to be lower in heterozygous females compared 
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with affected males (Felix et al., 1998). For diagnostic purpose the minimum frequency 
of fragile X metaphases recommended was 4% (Jacky et al., 1991). However, even 
lower cut-off points are commonly used in diagnostic laboratories. The limitations of the 
cytogenetic test were obvious in detecting clinically normal carriers. 
 
1.2.2 Direct mutation analysis (Southern Blot Analysis) 
 
Southern blot technique is a technique of transferring deoxyribonucleic acid (DNA) to a 
solid membrane support for subsequent hybridization with a specific probe. This method 
was introduced by Edward M Southern in 1975. By using this technique, complex 
population of DNA molecules can be screened for the existence of sequences associated 
to a selected probe.  
 
Methylated regions mapping in DNA using Southern blot are in fact based on the 
inability of methylation-sensitive restriction enzymes to cut sequences that contain 
methylated CpG site(s). This method can provide an estimation of the overall 
methylation status of CpG islands including some quantitative analysis (Issa et al., 
1994). However, Southern blot requires large amounts of high molecular weight DNA 
(generally 5 µg or more). 
 
Firstly in Southern blot technique, the DNA must be prepared and digested. Secondly, 
the fraction of DNA is separated according to size by agarose gel electrophoresis 
followed by transferring and fixation of the DNA onto the membrane. Hybridization of 
the membrane with a nucleic acid probe must then be done. After hybridization, the 
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membrane needs to be washed to remove the unspecific signal and lastly the hybridized 
probe will be subsequently detected.  
 
In the diagnosis of Fragile X Syndrome, Southern blot only allows an estimated 
measurement of the size of CGG repeat segments but at the same time, an accurate 
assessment of the methylation status can be assayed. Even though Southern blot analysis 
accurately detects alleles in large size ranges, precise sizing is still not possible. 
Moreover, Southern blot analysis is more labor intensive than PCR and requires larger 
quantities of genomic DNA (Sherman et al., 2005).  
 
1.2.3 Direct mutation analysis (Polymerase Chain Reaction) 
 
Polymerase chain reaction is a procedure that allows trace amounts of DNA to be 
quickly and repeatedly copied to produce a quantity sufficient to be analyzed using 
conventional laboratory methods. 
 
A typical PCR programme usually consists of a denaturing step, an annealing step, and 
an extension step. Denaturation is normally carried out at 94 – 95 ºC but principally, it 
begins at 70ºC. During denaturing, two strands of DNA template are separated from 
each other. At the same time, polymerase enzyme is denatured, nucleotides are 
degraded, and primers are depurinated.  
 
The temperature is then lowered to 55ºC so that oligonucleotide primer can hybridize on 
the single-stranded DNA template. Subsequent to that, the temperature is increased to 
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the optimal temperature for Taq polymerase which is 72ºC. As a consequence, the 
primer is elongated until a double-stranded DNA is formed, which is exactly equivalent 
to the original DNA template. For every cycle, the number of template DNAs will be 
doubled due to the complementation that occurs along both strands of the DNA 
templates.  
 
1.3 Alternative potential methods on Fragile X Syndrome Diagnosis 
1.3.1 Real Time PCR 
 
Real Time Polymerase Chain Reaction (Real-time PCR) is a technique that is widely 
used recently. Real-time PCR system is based on the detection and quantification of a 
fluorescent reporter (Dorak, 2006). In real time PCR, the fluorescence emitted is 
monitored during the reaction as a marker of amplicon production during each PCR 
cycle (in real time) compared to the endpoint detection. This signal increases in direct 
proportion to the amount of PCR product in a reaction.  
 
Real-time PCR that is also known as Quantitative Polymerase Chain Reaction (qPCR) is 
based on the revolutionary method of PCR. It is now has appear to be new and powerful 
application and widely used all over the world as the method of choice among scientist 
(Mark et al., 2005). The potential of Real-time PCR is not only for better quantification 
of the starting DNA amount in the samples of an amplification but also for the detection 
of gene copy number and gene expression (Mark et al., 2005). 
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However, high GC content is always present in the genomic target sequence and as in 
conventional PCR, these GC rich sequences can inhibit the amplification process. High 
GC content promotes the formation of alternative DNA structure (Marco et al., 2006). It 
can also generate the polymerase pause site which will cause errors during the 
replication process (Mahmoud et al., 2008).  
 
1.3.2 Taqman Chemistry 
 
Presently, the popular detection method used for PCR products is the dye-based methods 
that utilize an intercalating dye (e.g., SYBR Green I). However, in real time PCR this 
intercalating dye is added to the PCR mix. This dye will bind and detect all double-
stranded DNA that accumulates during the assay, regardless of the sequence of that 
DNA. Although this method offers great flexibility, it can unfortunately detect multiple 
amplicons that are generated by nonspecific priming as well as primer-dimers. 
 
However, probe-based detection format can be used to replace the dye-base detection 
method. The probe-based method use labeled and sequence-specific probe that will 
anneal between the primer sites and will only generate a signal when correct amplicon is 
produced. 
 
Taqman probe is one of the types of probe-based detection format. Taqman probe uses 
the hydrolysis probe format for real-time PCR detection. Technically, the hydrolysis 
probe format is a homogeneous 5´-nuclease assay, since a single 3´-non-extendable 
probe is cleaved during amplification. This single probe contains two labels near to each 
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other which are a fluorescent reporter dye at the 5´-end and a quencher label at or near 
the 3´-end. 
 
When the probe is intact, the fluorescent signal is almost completely suppressed by the 
quenching label. When the probe is hybridized to its target sequence, it is cleaved by the 
5´to 3´ exonuclease activity of the Taq DNA Polymerase, which “unquenches” the 
fluorescent reporter dye. During each PCR cycle, more of the released fluorescent dye 
accumulates, enhancing the fluorescent signal. 
 
1.3.3 Lock Nucleic Acid 
 
Lock Nucleic Acids (LNAs) are a novel nucleic acid analog and are used in probes and 
primers that require high oligonuleotide hybridization strength and specificity. Lock 
Nucleic Acid (LNA) Probe contains a 2’-O, 4’-C methylene bridge (figure 1.3). This 
bridge restricts the flexibility of the ribofuranose ring and locks the structure into a rigid 
bicyclic formation that lead to enhance hybridization performance and excellent 
biological stability.  
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Figure 1.3: The differences in the structure between RNA and LNA monomer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
